Please ensure Javascript is enabled for purposes of website accessibility

Why Celator Pharmaceuticals, Inc. Soared Higher Today

By Todd Campbell - Mar 21, 2016 at 3:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Management plans to file for regulator approval of its cancer drug Vyxeos this year.

SOURCE: CELATOR PHARMACEUTICALS

What: Following the release of its fourth quarter and full year financials, shares of Celator Pharmaceuticals (NASDAQ: CPXX) are rallying 10.8% at 3:30 p.m. Monday.

So what: This tiny market cap biotech recently surprised investors with bullish phase 3 trial results for Vyxeos, a nano-scale liposome encased mash-up of the chemotherapy drugs cytarabine and daunorubicin, that sent shares surging 450%, and on Monday, the company updated investors on its timeline for regulatory filings for Vyxeos approval.

CPXX Total Return Price Chart

CPXX Total Return Price data by YCharts

In trials, overall survival in secondary acute myeloid leukemia (AML) patients receiving Vyxeos was 9.56 months and that was significantly better than the 5.95 months experienced within the control arm of the study, which was given the standard combination of cytarabine and daunorubicin.

Today, management reinforced its plans to file for FDA approval of Vyxeos in the third quarter and to similarly file for EU approval by the end of Q1, 2017.

Now what: Secondary AML is notoriously tough-to-treat and there have been few treatment advances in the indication over the past decade. Although Celator Pharmaceuticals' Vyxeos is still a chemotherapy, and therefore, still poses safety risks, the fact that it delivered best-in-class efficacy with a similar safety profile to standard-of-care suggests it may revolutionize patient treatment.

Investors should remember, however, that Celator Pharmaceuticals is a clinical stage company with no revenue and just $23 million in cash on its books exiting December.

Management firmed up its cash position by raising an additional $9.8 million in Q1 via an at-the-market offering, but even so, guidance is for that cash to run out in mid-2017. Given that the company's filing timeline means that a FDA decision wouldn't be likely until about the same time, there's a good possibility that Celator Pharmaceuticals will need to tap markets for additional financing at some point to fuel the commercial launch of Vyxeos next year. Because of that, investors should still approach this company cautiously, because any stumble in its timeline, or with Vyxeos FDA application, could take a big toll on the company's shares.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.